Novel agents for the treatment of B-ALL include blinatumomab, a bispecific T-cell engager with a dual specificity for CD19 and CD3 that directs cytotoxic T cells activity against malignant CD19-positive B cells. This evidence concerns the gene CD19 and precursor B-cell acute lymphoblastic leukemia.